Related Experiment Video

Updated: Apr 24, 2026

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

7.8K

Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma

Laia Rosich1, Arnau Montraveta1, Sílvia Xargay-Torrent1

  • 1Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Oncotarget
|September 13, 2014
PubMed

Insights

Dual PI3K/mTOR inhibition with NVP-BEZ235 shows superior efficacy in mantle cell lymphoma (MCL) treatment compared to single inhibitors. This approach effectively blocks key signaling pathways and microenvironmental processes, offering a promising therapeutic strategy for MCL.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The Phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is crucial in mantle cell lymphoma (MCL) development and resistance.
  • mTOR inhibitors show antitumor activity but face limitations due to feedback loop activation.

Purpose of the Study:

  • To comparatively analyze the efficacy of an mTOR inhibitor (everolimus), a pan-PI3K inhibitor (NVP-BKM120), and a dual PI3K/mTOR inhibitor (NVP-BEZ235) in primary MCL cells.
  • To evaluate the potential of multi-level PI3K/Akt/mTOR pathway inhibition for MCL treatment.

Main Methods:

  • Comparative analysis of everolimus, NVP-BKM120, and NVP-BEZ235 in primary MCL cells.
  • Assessment of PI3K/Akt/mTOR signaling inhibition, gene expression profiling, and functional validation (angiogenesis, migration, invasiveness).
  • Evaluation of effects on IL4 and IL6/STAT3 signaling pathways.

Main Results:

  • NVP-BEZ235 demonstrated superior inhibition of PI3K/Akt/mTOR signaling compared to everolimus and NVP-BKM120.
  • NVP-BEZ235 significantly altered gene expression profiles and inhibited angiogenesis, migration, and tumor invasiveness.
  • NVP-BEZ235 uniquely blocked IL4 and IL6/STAT3 signaling, which can impair chemotherapy efficacy.

Conclusions:

  • Targeting the PI3K/Akt/mTOR pathway at multiple levels, particularly with dual inhibitors like NVP-BEZ235, is a more effective strategy for MCL treatment.
  • NVP-BEZ235 shows promise in disrupting microenvironment-related processes in MCL, suggesting its potential as a therapeutic agent.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

941
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.1K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.6K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.1K